Adults with Severe or Moderately Severe Hemophilia B Receiving Etranacogene Dezaparvovec in the HOPE-B Phase 3 Clinical Trial Continue to Experience a Stable Increase in Mean Factor IX Activity Levels and Durable Hemostatic Protection after 24 Months’ Follow-up
- Resource Type
- Source
- Blood. 140:4910-4912
- Subject
Immunology Cell Biology Hematology Biochemistry - Language
- ISSN
- 1528-0020
0006-4971